<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674880</url>
  </required_header>
  <id_info>
    <org_study_id>15.1(15PT).15 ComEt-CBM</org_study_id>
    <nct_id>NCT02674880</nct_id>
  </id_info>
  <brief_title>Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance</brief_title>
  <acronym>HAEC-DONA</acronym>
  <official_title>Use of High-molecular Weight Hyaluronan in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Diseases Treated With Non-invasive Ventilation: Feasibility and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the effect of HMW-HA on NIV effectiveness in patients
      admitted to a sub-intensive care unit for respiratory failure due to acute exacerbation of
      COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to test the effect of HMW-HA on NIV effectiveness in patients
      admitted to a sub-intensive care unit for respiratory failure due to acute exacerbation of
      COPD. The design is a parallel-arm, single-blind, placebo-controlled randomized clinical
      trial. Eighty patients, aged eighteen years or older, admitted for respiratory failure
      primarily due to COPD exacerbation and requiring non-invasive ventilation will be enrolled
      and randomized to the study treatment (active or placebo).

      All patients will be treated with NIV delivered using a Hamilton C1 ventilator and medical
      therapy according to current guidelines (inhaled long-acting b2 agonists, inhaled long-acting
      anticholinergic, inhaled and systemic corticosteroids, antibiotics). Patients randomized to
      the active intervention group will also receive HMW-HA (Yabro® - 5 ml of saline containing
      0.3% hyaluronic acid sodium salt) via nebulizer b.i.d., while patients randomized in the
      control group will receive a matching placebo. Patients will be treated until weaning or
      until NIV failure, defined as oro-tracheal intubation or death.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative time on NIV</measure>
    <time_frame>Day 1-10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of decline of time on NIV</measure>
    <time_frame>Day 1-10</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Indices of NIV efficacy over one week of treatment</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HMW-HA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 ml of saline via nebulizer b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMW-HA</intervention_name>
    <description>Aerolized administration b.i.d.</description>
    <arm_group_label>HMW-HA</arm_group_label>
    <other_name>Yabro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years of age or older

          -  Admitted for respiratory failure primarily due to COPD exacerbation

          -  Requiring non-invasive ventilation

          -  Respiratory distress, as evidenced by moderate-to-severe dyspnea and use of accessory
             muscles of respiration

          -  Hypercapnic respiratory failure

          -  High respiratory rate

        Exclusion Criteria:

          -  Respiratory arrest or the need for immediate intubation

          -  Upper airways obstruction

          -  Facial trauma

          -  Inability to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaele Antonelli Incalzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università Campus Biomedico di Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raffaele Antonelli Incalzi, MD</last_name>
    <phone>Tel.: (+39) 06.22541.653</phone>
    <email>r.antonelli@unicampus.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Università Campus Biomedico di Roma</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaele Antonelli Incalzi, MD</last_name>
      <phone>+39 06 225411365</phone>
      <email>r.antonelli@unicampus.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Raffaele Antonelli Incalzi</investigator_full_name>
    <investigator_title>Professore Ordinario, Settore scientifico MED/09</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

